<DOC>
	<DOCNO>NCT00002915</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness penclomedine treat patient advance solid tumor .</brief_summary>
	<brief_title>Penclomedine Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose oral penclomedine administer daily 5 day every 4 week patient advance solid tumor malignancy . II . Describe quantitate toxic effect penclomedine administer schedule patient . III . Study clinical pharmacology metabolism penclomedine schedule , seek pharmacodynamic correlate pharmacologic parameter clinical endpoint . IV . Study bioavailability oral penclomedine , qualitatively compare metabolite profile produce follow oral intravenous administration patient . V. Seek preliminary evidence therapeutic activity penclomedine patient advance cancer . OUTLINE : This dose-escalation study estimate maximum tolerate dose ( MTD ) penclomedine . Cohorts 3-6 patient treat escalate dos MTD reach . Patients receive oral penclomedine 5 consecutive day every 4 week . If tumor progression unacceptable toxicity document treatment course , patient remove study . A total 10 patient treat dose determine MTD ( recommend phase II dose ) . PROJECTED ACCRUAL : An estimated 20 patient accrue approximately 10 month .</detailed_description>
	<mesh_term>Penclomedine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically document solid tumor refractory conventional therapy conventional treatment exist No primary secondary brain tumor No CNS disease treatmentrelated CNS dysfunction No bone metastases involve 4 site PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Life expectancy : At least 8 week Hematopoietic : Absolute neutrophil count great 1,500 Platelet count great 100,000 Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 1.5 mg/dL Other : No active infection No history egg protein allergy No prior gastric small intestine resection clinical evidence malabsorption No history medical , neurologic , psychiatric disorder No concomitant medical problem unrelated malignancy precludes study compliance increase treatment risk No pregnant woman Adequate contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : No 4 course combination chemotherapy include alkylating agent , cisplatin , carboplatin ( applies grade 1 bad myelosuppression report study ) No prior mitomycin nitrosoureas At least 28 day since chemotherapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy wide port involve pelvis 20 % bone marrow At least 28 day since largefield radiotherapy No concurrent radiotherapy Surgery : At least 14 day since major surgery Other : No bone marrow transplantation</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>